Mode
Text Size
Log in / Sign up

Mendelian Randomization review links Lp(a) to inflammatory protein pathways

Mendelian Randomization review links Lp(a) to inflammatory protein pathways
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider that Lp(a) may influence cardiovascular risk through inflammatory pathways, based on genetic association evidence.

This is a Mendelian Randomization analysis, not a primary clinical trial. The scope was to use genetic instruments for Lp(a) blood concentrations to identify associated proteins and pathways relevant to major adverse cardiovascular events (MACE).

The authors identified a total of 521 proteins associated with Lp(a). Pathway enrichment analysis then highlighted 91 Lp(a) downstream proteins comprising MACE-relevant pathways. These pathways include oxidized phospholipid-related processes, chemotaxis of immune cells, endothelial cell activation, pro-inflammatory monocyte activation, neutrophil activity, coagulation, and lipid metabolism.

The analysis is observational in nature, using genetic proxies to infer associations. The authors note that the results suggest the influence of Lp(a) may be primarily through modifying inflammation rather than lipid-lowering, providing a mechanistic framework. However, the study does not report effect sizes, p-values, confidence intervals, or a specific study population.

Limitations include the inferential nature of Mendelian Randomization and the lack of reported statistical measures for the protein associations. Practice relevance is restrained; the findings offer insight into potential biological mechanisms but do not provide direct evidence for clinical interventions or trial outcomes.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Elevated lipoprotein(a) [Lp(a)] is a known risk factor for several cardiovascular-related diseases established from multiple genetic and observational studies. However, the underlying mechanisms mediating the effects of Lp(a) levels on cardiovascular disease risk and major adverse cardiovascular events (MACE) are unclear. The aim of this study was to identify proteins downstream of Lp(a) using mendelian randomization (MR) - a genetic causal inference approach. Methods: A two-sample MR was performed by initially identifying Lp(a) genetic instruments based on data from genome wide association studies (GWAS) of Lp(a) blood concentrations. These instruments were then tested for association with proteins from proteomic pQTL data (Olink from UK Biobank, 2940 proteins and SomaScan from deCODE, 4907 proteins). Results: A total of 521 proteins associated with Lp(a) were identified. Using pathway enrichment analysis, the following MACE-relevant pathways were identified comprising a total of 91 Lp(a) downstream proteins: oxidized phospholipid-related, chemotaxis of immune cells and endothelial cell activation, pro-inflammatory monocyte activation, neutrophil activity, coagulation, and lipid metabolism. Conclusion: The results suggest that the influence of Lp(a) treatments is primarily through modifying inflammation rather than lipid-lowering, thus providing insight into the mechanistic framework which mediates the effects of elevated Lp(a) on atherosclerotic cardiovascular disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.